Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Eupraxia Pharmaceuticals Inc
EPRXEupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Address: 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
Analytics
Objectif de Cours de WallStreet
17.41 CADRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés EPRX
Analyse des dividendes EPRX
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes EPRX
Valorisation des titres EPRX
financières EPRX
Résultats | 2019 | Dynamique |